Agios/AGIO

$34.00

3.43%
-
1D1W1MYTD1YMAX

About Agios

Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.

Ticker

AGIO

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jacqualyn Fouse

Employees

383

Headquarters

Cambridge, United States

Agios Metrics

BasicAdvanced
$1.85B
Market cap
-
P/E ratio
-$6.33
EPS
0.84
Beta
-
Dividend rate

What the Analysts think about Agios

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 5 analysts.
25.88% upside
High $49.00
Low $29.00
$34.00
Current price
$42.80
Average price target

Agios Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-1,350.7% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$7.1M
-2.74%
Net income
$-95.9M
5.04%
Profit margin
-1,350.7%
8%

Agios Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.38%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$1.47
-$1.51
-$1.64
-$1.72
-
Expected
-$1.70
-$1.56
-$1.70
-$1.65
-$1.64
Surprise
-13.59%
-3.27%
-3.67%
4.38%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Agios stock

Buy or sell Agios stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing